Immunogenicity of synthetic saccharide fragments of<i>Vibrio cholerae</i>O1 (Ogawa and Inaba) bound to Exotoxin A

Wade, Terri K.; Saksena, Rina; Shiloach, Joseph; Kòváč, Pavol; Wade, William F.

doi:10.1111/j.1574-695x.2006.00143.x

Cited by 16 publications

(4 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, they compared immunologically the P. aeruginosa rEPA conjugates of Ogawa and Inaba serotype O -antigen oligosaccharides and found that the conjugates of Ogawa oligosaccharides boosted Inaba-primed mice, whereas the conjugates of Inaba oligosaccharides could not boost Ogawa-primed mice. This result implies that Ogawa and Inaba LPSs contain different immunodominant epitopes …”

Section: Semi- and Fully Synthetic Carbohydrate-based Antibacterial C...mentioning

confidence: 91%

“…This result implies that Ogawa and Inaba LPSs contain different immunodominant epitopes. 214 The first emergence of a new V. cholerae serotype O139 was noticed in the southern part of India in 1992 and becomes the non-O1 V. cholerae serotype to cause epidemic cholera. 215 V. cholerae O139 possess a high molecular weight CPS, in distinctive composition from the LPS antigen.…”

Section: Acs Infectiousmentioning

confidence: 99%

See 1 more Smart Citation

Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines

Rohokale

Guo

2023

ACS Infect. Dis.

View full text Add to dashboard Cite

The surface of cells is coated with a dense layer of glycans, known as the cell glycocalyx. The complex glycans in the glycocalyx are involved in various biological events, such as bacterial pathogenesis, protection of bacteria from environmental stresses, etc. Polysaccharides on the bacterial cell surface are highly conserved and accessible molecules, and thus they are excellent immunological targets. Consequently, bacterial polysaccharides and their repeating units have been extensively studied as antigens for the development of antibacterial vaccines. This Review surveys the recent developments in the synthetic and immunological investigations of bacterial polysaccharide repeating unit-based conjugate vaccines against several human pathogenic bacteria. The major challenges associated with the development of functional carbohydrate-based antibacterial conjugate vaccines are also considered.

show abstract

Section: Semi- and Fully Synthetic Carbohydrate-based Antibacterial C...mentioning

confidence: 91%

Section: Acs Infectiousmentioning

confidence: 99%

Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines

Rohokale

Guo

2023

ACS Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…In a subsequent study, the hexasaccharides corresponding to Ogawa and Inaba serotypes of V. cholerae O:1 were prepared by a [4 + 2] assembling strategy, converted into their squaric acid derivatives and conjugated with recombinant exotoxin A from Pseudomonas aeruginosa (rEPA) 64. The results of the immunological tests highlighted the fact that Ogawa and Inaba LPS contain different immunodominant epitopes: Ogawa neoglycoconjugates can boost Inaba‐primed mice, but Inaba neoglycoconjugates cannot boost Ogawa‐primed mice 65. More recently, an improved synthetic approach to the Ogawa terminal hexasaccharide was described by the same authors.…”

Section: Antibacterial Vaccinesmentioning

confidence: 99%

Carbohydrates and Immunology: Synthetic Oligosaccharide Antigens for Vaccine Formulation

2011

View full text Add to dashboard Cite

Despite the enormous progress achieved by modern medicine, numerous diseases still have a profound impact on public health. Infectious diseases caused by a variety of microorganisms (viruses, fungi and parasites) and bacteria are a global major concern and, because of the emergence, for instance, of multidrug resistance, not only in developing countries. The development of preventative therapies, such as the rational design of novel and more efficient vaccines, might offer a solution to this state of affairs and other associated drawbacks. Vaccination is considered by the World Health Organization to be the most cost‐effective strategy for controlling infectious disease, because it should confer long‐term protective immunity in the population. A second consideration involves cancer. The outstanding progress achieved in the identification and structural characterization of tumour‐associated antigens has prompted their employment in tumour immunotherapy, on the basis of the observation that tumour cells possess specific antigens that can be recognized by an immune system appropriately conditioned to the task. Carbohydrates play key roles in many molecular recognition phenomena and they can affect any kind of interaction with the immune system. Saccharide‐based antigens (bacterial capsular polysaccharides or tumour‐associated carbohydrate antigens, for instance) have therefore been studied and employed in the formulation of vaccines. In recent years there has been increasing use of synthetic saccharide antigens for the formulation of vaccine candidates. These structures are indeed chemically well defined, devoid of biologic contaminants and, in principle, available in large amounts, relative to materials extracted from natural sources. In addition, synthetic saccharide antigens can also serve as haptens in protein conjugates, eliciting highly specific antibodies in animal models and humans. The great potential of synthetic saccharide antigens is attested to by the spectacular success of the Cuban vaccine against Haemophilus influenzae type b. Here we review the major advances in the development of synthetic carbohydrate‐based vaccines targeted against infectious diseases and cancer.

show abstract

“…OSP is attached to lipid A that is part of the outer membrane of V. cholerae [9]. We have previously shown that a synthetic neoglyconjugate cholera vaccine containing a hexasaccharide of V. cholerae O1 Ogawa is protectively immunogenic in mice [10]–[12]. We were therefore interested in evaluating whether a cholera conjugate vaccine containing native OSP recovered from V. cholerae O1 would also be immunogenic.…”

Section: Introductionmentioning

confidence: 99%

Evaluation in Mice of a Conjugate Vaccine for Cholera Made from Vibrio cholerae O1 (Ogawa) O-Specific Polysaccharide

Alam

Bufano

et al. 2014

PLoS Negl Trop Dis

Self Cite

View full text Add to dashboard Cite

BackgroundProtective immunity against cholera is serogroup specific. Serogroup specificity in Vibrio cholerae is determined by the O-specific polysaccharide (OSP) of lipopolysaccharide (LPS). Generally, polysaccharides are poorly immunogenic, especially in young children.MethodologyHere we report the evaluation in mice of a conjugate vaccine for cholera (OSP:TThc) made from V. cholerae O1 Ogawa O-Specific Polysaccharide–core (OSP) and recombinant tetanus toxoid heavy chain fragment (TThc). We immunized mice intramuscularly on days 0, 21, and 42 with OSP:TThc or OSP only, with or without dmLT, a non-toxigenic immunoadjuvant derived from heat labile toxin of Escherichia coli.Principal FindingsWe detected significant serum IgG antibody responses targeting OSP following a single immunization in mice receiving OSP:TThc with or without adjuvant. Anti-LPS IgG responses were detected following a second immunization in these cohorts. No anti-OSP or anti-LPS IgG responses were detected at any time in animals receiving un-conjugated OSP with or without immunoadjuvant, and in animals receiving immunoadjuvant alone. Responses were highest following immunization with adjuvant. Serum anti-OSP IgM responses were detected in mice receiving OSP:TThc with or without immunoadjuvant, and in mice receiving unconjugated OSP. Serum anti-LPS IgM and vibriocidal responses were detected in all vaccine cohorts except in mice receiving immunoadjuvant alone. No significant IgA anti-OSP or anti-LPS responses developed in any group. Administration of OSP:TThc and adjuvant also induced memory B cell responses targeting OSP and resulted in 95% protective efficacy in a mouse lethality cholera challenge model.ConclusionWe describe a protectively immunogenic cholera conjugate in mice. Development of a cholera conjugate vaccine could assist in inducing long-term protective immunity, especially in young children who respond poorly to polysaccharide antigens.

show abstract

Immunogenicity of synthetic saccharide fragments ofVibrio choleraeO1 (Ogawa and Inaba) bound to Exotoxin A

Cited by 16 publications

References 40 publications

Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines

Development in the Concept of Bacterial Polysaccharide Repeating Unit-Based Antibacterial Conjugate Vaccines

Carbohydrates and Immunology: Synthetic Oligosaccharide Antigens for Vaccine Formulation

Evaluation in Mice of a Conjugate Vaccine for Cholera Made from Vibrio cholerae O1 (Ogawa) O-Specific Polysaccharide

Contact Info

Product

Resources

About